Incyte Corporation reported Jakafi (ruxolitinib) net sales of $620 million for the third quarter of 2023 [1]. This represents a 9% increase compared to the $569 million in net sales recorded for the same period in 2022 [1].
What drove Jakafi's sales growth in Q3 2023?
The increase in Jakafi sales during the third quarter of 2023 was primarily driven by continued growth across its approved indications [1]. This includes its use in myelofibrosis (MF) and polycythemia vera (PV), where Jakafi is a foundational therapy [1]. Sales also benefited from the ongoing launch and uptake of Jakafi in its indication for acute graft versus host disease (GVHD) [1].
How do Jakafi's sales compare to previous quarters?
In the second quarter of 2023, Incyte reported Jakafi net sales of $610 million [1]. The $620 million in sales for Q3 2023 shows a continued upward trend [1].
What is Incyte's outlook for Jakafi sales?
For the full year 2023, Incyte expects Jakafi net sales to be between $2.41 billion and $2.46 billion [1]. This guidance reflects the company's confidence in Jakafi's sustained performance [1].
When does Jakafi's patent protection expire?
Jakafi's patent exclusivity is a key factor in its sustained sales [2]. DrugPatentWatch.com provides detailed information on patent expiries and other intellectual property aspects for pharmaceuticals like Jakafi [2]. The specific patent expiry dates for Jakafi are complex due to multiple patents covering different aspects of the drug and its uses [2]. However, the core patent for ruxolitinib is expected to expire in the coming years, opening the door for potential generic competition [2].
What is the global status of Jakafi sales?
Globally, Jakafi is marketed by Incyte in the United States and Canada, while Novartis markets it as Jakavi outside of these territories [1]. The sales figures reported by Incyte for Q3 2023 refer to their territory [1].
Sources:
[1] Incyte Corporation Q3 2023 Earnings Call Transcript, October 26, 2023
[2] DrugPatentWatch.com